Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs

Question 81: What is the therapeutic plasma level of digoxin?

A. 0.1-0.3 ng/ml
B. 0.8-1.5 ng/ml (Correct Answer)
C. 1.2-2 ng/ml
D. > 2.4 ng/ml

Explanation: **Explanation:** Digoxin is a cardiac glycoside with a **narrow therapeutic index**, meaning the margin between the effective dose and the toxic dose is very slim. Therapeutic Drug Monitoring (TDM) is essential for its safe use. 1. **Why Option B is Correct:** The established therapeutic plasma concentration for Digoxin is generally **0.8–1.5 ng/ml** (some texts suggest 0.5–2.0 ng/ml). Within this range, Digoxin effectively increases myocardial contractility (positive inotropy) and decreases heart rate (negative chronotropy) without causing significant toxicity. In patients with Heart Failure, lower levels (0.5–0.9 ng/ml) are often preferred to reduce mortality risk. 2. **Why Other Options are Incorrect:** * **Option A (0.1-0.3 ng/ml):** These levels are sub-therapeutic and will not provide the desired clinical effect. * **Option C (1.2-2 ng/ml):** While the upper limit of 2.0 ng/ml is sometimes accepted, this range borders on toxicity. Most modern guidelines aim for levels below 1.5 ng/ml to ensure safety. * **Option D (> 2.4 ng/ml):** This is the **toxic range**. Levels above 2.0–2.4 ng/ml are associated with digitalis toxicity, manifesting as arrhythmias, nausea, and visual disturbances (xanthopsia). **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Inhibits Na+/K+ ATPase pump. * **Toxicity Trigger:** **Hypokalemia** (potassium competes with digoxin for the binding site; low K+ allows more digoxin to bind, increasing toxicity). * **ECG Changes:** Characterized by a "reverse tick" or "hockey stick" appearance (ST-segment depression). * **Antidote:** Digoxin Immune Fab (Digibind). * **Sampling Time:** TDM should be performed at least 6–8 hours after the last dose to allow for tissue distribution.

Question 82: A pharmacologist is determining the pharmacokinetic parameters of a novel antibiotic. The drug is a weak organic acid with a pKa of 3.0. Assuming a pH of 2.0 in the stomach, approximately what percent of the drug will be in a form that can be rapidly absorbed from the stomach?

A. 60%
B. 50%
C. 99%
D. 90% (Correct Answer)

Explanation: ### Explanation **1. Understanding the Correct Answer (D: 90%)** The absorption of a drug across biological membranes depends on its ionization state; only the **non-ionized (lipid-soluble)** form can be rapidly absorbed. This relationship is governed by the **Henderson-Hasselbalch equation**. For a **weak acid**: $pH - pKa = \log \frac{[Ionized]}{[Non-ionized]}$ Plugging in the values: * $2.0 - 3.0 = \log \frac{[I]}{[NI]}$ * $-1 = \log \frac{[I]}{[NI]}$ * $10^{-1} = \frac{[I]}{[NI]} \Rightarrow \frac{1}{10} = \frac{[I]}{[NI]}$ This means there is **1 part ionized** for every **10 parts non-ionized**. To find the percentage of the absorbable (non-ionized) form: $\frac{NI}{Total} \times 100 = \frac{10}{1 + 10} \times 100 = \frac{10}{11} \times 100 \approx \mathbf{90.9\%}$ **2. Why Other Options are Incorrect** * **A & B (60%, 50%):** These values would occur if the pH were closer to the pKa. When $pH = pKa$, the drug is 50% ionized and 50% non-ionized. * **C (99%):** This would occur if the pH were 2 units below the pKa (i.e., pH 1.0). A difference of 1 pH unit results in a 10:1 ratio (~90%), while 2 units result in a 100:1 ratio (~99%). **3. Clinical Pearls & High-Yield Facts** * **The "Like in Like" Rule:** Weak acids are better absorbed in acidic mediums (stomach), and weak bases are better absorbed in basic mediums (intestine). * **Ion Trapping:** This principle is used clinically to treat toxicity. To excrete a weak acid (e.g., Aspirin), we **alkalinize the urine** with Sodium Bicarbonate. This increases the ionized fraction in the renal tubule, "trapping" the drug in the urine and preventing reabsorption. * **Rule of Thumb:** If $pH - pKa = 1$, the ratio is 90:10. If the difference is 2, the ratio is 99:1. If the difference is 3, the ratio is 99.9:0.1.

Question 83: Therapeutic drug monitoring of plasma concentrations of antihypertensive drugs is NOT practiced because:

A. Determination of plasma levels of these drugs is a tedious and lengthy process.
B. It is easier to measure the clinical effect of these drugs. (Correct Answer)
C. The antihypertensive effect does not increase linearly with the dose.
D. All antihypertensive drugs are prodrugs.

Explanation: ### Explanation **1. Why Option B is Correct:** The fundamental principle of **Therapeutic Drug Monitoring (TDM)** is to use plasma drug concentrations as a surrogate marker for clinical efficacy or toxicity when the clinical effect itself is difficult to measure. In the case of antihypertensive drugs, the clinical effect—**Blood Pressure (BP)**—is easily, non-invasively, and accurately measured using a sphygmomanometer. Since the goal of therapy is to achieve a target BP rather than a specific plasma level, monitoring the clinical response is more practical and direct than measuring drug concentrations. **2. Why Other Options are Incorrect:** * **Option A:** While some assays are complex, modern chromatography (HPLC/LC-MS) makes measuring drug levels routine. The lack of TDM is due to clinical irrelevance, not technical difficulty. * **Option C:** While some drugs show non-linear kinetics, TDM is actually *more* indicated for drugs with non-linear pharmacokinetics (e.g., Phenytoin) to avoid toxicity. * **Option D:** Only a few antihypertensives are prodrugs (e.g., Enalapril, Methyldopa). Even for prodrugs, one could theoretically monitor active metabolites if necessary. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Indications for TDM:** 1. **Narrow Therapeutic Index:** Digoxin, Lithium, Theophylline, Aminoglycosides, Tricyclic Antidepressants (TCAs). 2. **Poorly defined clinical end-points:** Antiepileptics (you cannot "measure" a seizure that hasn't happened yet). 3. **To check compliance:** Especially in psychiatric or chronic asymptomatic conditions. * **Drugs NOT requiring TDM:** 1. Drugs with **easily measurable physiological markers:** Antihypertensives (BP), Hypoglycemics (Blood glucose), Anticoagulants (PT/INR or aPTT). 2. **Hit-and-run drugs:** Where the effect lasts much longer than the plasma half-life (e.g., Reserpine, MAO inhibitors, Omeprazole).

Question 84: Hofmann elimination is defined as:

A. Inactivation of a drug by a metabolizing enzyme.
B. Unchanged excretion of a drug by the kidney.
C. Excretion of a drug in the feces.
D. Inactivation of a drug through molecular rearrangement. (Correct Answer)

Explanation: ### Explanation **Hofmann elimination** is a unique pharmacokinetic process where a drug undergoes spontaneous non-enzymatic degradation in the plasma and tissues. **1. Why Option D is Correct:** The correct answer is **inactivation through molecular rearrangement**. Unlike most drugs that require hepatic enzymes or renal clearance, drugs undergoing Hofmann elimination break down spontaneously due to the specific pH and temperature of the body. This involves a chemical rearrangement (specifically, a base-catalyzed elimination) that splits the molecule into inactive metabolites. **2. Why Other Options are Incorrect:** * **Option A:** This describes **biotransformation** (metabolism), typically occurring in the liver via Cytochrome P450 enzymes. Hofmann elimination is specifically *non-enzymatic*. * **Option B:** This refers to **renal excretion**, the primary route for water-soluble drugs like aminoglycosides. * **Option C:** This refers to **biliary or fecal excretion**, common for large molecular weight compounds or unabsorbed drugs. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Prototype Drug:** **Atracurium** and its isomer **Cisatracurium** (Skeletal muscle relaxants). * **Clinical Advantage:** Because it does not rely on the liver or kidneys, Atracurium is the **neuromuscular blocker of choice in patients with hepatic or renal failure**. * **Factors Affecting Rate:** Since it is a chemical reaction, the rate of Hofmann elimination increases with **Hyperthermia** and **Alkalosis** (high pH), and decreases with Hypothermia and Acidosis. * **Metabolite Note:** The breakdown of Atracurium produces **Laudanosine**, which can cross the blood-brain barrier and potentially cause seizures (though this is less common with Cisatracurium).

Question 85: Which of the following drugs acts as a microsomal enzyme inhibitor?

A. Rifampicin
B. Cimetidine (Correct Answer)
C. Phenobarbitone
D. Phenytoin

Explanation: **Explanation:** The correct answer is **Cimetidine**. This question tests the fundamental pharmacological concept of drug metabolism via the Cytochrome P450 (CYP450) enzyme system. **1. Why Cimetidine is Correct:** Cimetidine is a classic **microsomal enzyme inhibitor**. It binds to the heme iron of the CYP450 oxidase system, reducing the metabolic activity of enzymes like CYP1A2, CYP2C9, and CYP3A4. When an inhibitor is co-administered with other drugs (e.g., Warfarin or Theophylline), it decreases their metabolism, leading to increased plasma levels and potential toxicity. **2. Why the Other Options are Incorrect:** * **Rifampicin, Phenobarbitone, and Phenytoin** are all potent **microsomal enzyme inducers**. * Inducers increase the synthesis of CYP450 enzymes. This accelerates the metabolism of co-administered drugs, leading to decreased therapeutic efficacy (e.g., failure of oral contraceptives when taken with Rifampicin). **3. High-Yield Clinical Pearls for NEET-PG:** To remember these for the exam, use these popular mnemonics: * **Enzyme Inhibitors (VITAMIN K):** **V**alproate, **I**soniazid, **T**ame (Cimetidine), **A**miodarone, **M**acrolides (except Azithromycin), **I**ndinavir, **N**etilmicin (and other Azoles like Ketoconazole), **K**etoconazole. *Also: Grapefruit juice.* * **Enzyme Inducers (GPRS Cell Phone):** **G**riseofulvin, **P**henytoin, **R**ifampicin, **S**moking, **C**arbamazepine, **P**henobarbitone. **Key Fact:** Cimetidine is unique among H2 blockers for this effect; newer agents like Ranitidine and Famotidine have negligible effects on microsomal enzymes, making them safer regarding drug interactions.

Question 86: Which of the following drugs is deposited in the muscles?

A. Verapamil
B. Digoxin (Correct Answer)
C. Adenosine
D. Phenytoin

Explanation: **Explanation:** The correct answer is **Digoxin**. This question tests the concept of **Volume of Distribution ($V_d$)** and tissue-specific binding. **Why Digoxin is correct:** Digoxin has a very high volume of distribution (approx. 5–7 L/kg) because it is extensively sequestered in peripheral tissues, particularly **skeletal muscle**, as well as the heart, liver, and kidneys. It binds to the **Na+/K+-ATPase pump** in these tissues. Because skeletal muscle represents a large percentage of total body mass, it acts as the primary reservoir for Digoxin. * **Clinical Note:** In obese patients, Digoxin dosage should be calculated based on **Lean Body Weight (LBW)** rather than total body weight, as it does not distribute significantly into adipose tissue. **Why the other options are incorrect:** * **Verapamil:** While it has a large $V_d$, it is primarily metabolized by the liver and does not show the characteristic high-affinity skeletal muscle deposition seen with Digoxin. * **Adenosine:** It has an extremely short half-life (<10 seconds) because it is rapidly taken up by erythrocytes and vascular endothelial cells and metabolized. It does not stay in the system long enough for tissue deposition. * **Phenytoin:** It is highly protein-bound (primarily to albumin) in the plasma. Its distribution is more limited compared to Digoxin, and it follows zero-order kinetics at high therapeutic concentrations. **High-Yield Pearls for NEET-PG:** 1. **Tissue Reservoirs:** * **Muscle:** Digoxin, Emetine. * **Adipose Tissue:** Thiopentone, DDT. * **Bone/Teeth:** Tetracyclines, Heavy metals (Lead). * **Retina:** Chloroquine (binds to melanin). * **Liver:** Chloroquine, Emetine, Vitamin B12. 2. **Loading Dose:** Drugs with a high $V_d$ (like Digoxin) require a loading dose to achieve rapid therapeutic plasma concentrations. 3. **Dialysis:** Drugs with high $V_d$ (like Digoxin and Tricyclic Antidepressants) **cannot** be effectively removed by hemodialysis during toxicity.

Question 87: Which of the following is a prodrug?

A. Levodopa (Correct Answer)
B. Pioglitazone
C. Dexamethasone
D. Captopril

Explanation: **Explanation:** A **prodrug** is a pharmacologically inactive compound that must undergo metabolic conversion (usually in the liver or target tissues) to become an active drug. **Why Levodopa is correct:** Levodopa is the classic example of a prodrug used in Parkinsonism. It is an amino acid precursor of dopamine. While dopamine itself cannot cross the blood-brain barrier (BBB), Levodopa crosses the BBB via large neutral amino acid transporters. Once inside the CNS, it is decarboxylated by the enzyme **Dopa-decarboxylase** into its active form, **Dopamine**, which then acts on striatal receptors. **Why the other options are incorrect:** * **Pioglitazone:** This is an active Thiazolidinedione used in Type 2 Diabetes. It acts directly on PPAR-gamma receptors without requiring metabolic activation. * **Dexamethasone:** A potent glucocorticoid that is active in its administered form. (Note: *Prednisone* is a prodrug converted to *Prednisolone*, but Dexamethasone is not). * **Captopril:** Most ACE inhibitors are prodrugs (e.g., Enalapril to Enalaprilat), but **Captopril and Lisinopril** are the two notable exceptions—they are active drugs. **High-Yield Clinical Pearls for NEET-PG:** * **ACE Inhibitor Rule:** All ACE inhibitors are prodrugs except **Captopril** and **Lisinopril**. * **Active Metabolites:** Some drugs are active themselves but also have active metabolites (e.g., Diazepam to Nordiazepam). * **Common Prodrugs Mnemonic (All Prefer Drugs In Clear Liquid Form):** **A**CE inhibitors (most), **P**roguanil, **D**ipivefrin, **I**rinosan, **C**yclophosphamide, **L**evodopa, **F**luorouracil (5-FU).

Question 88: A patient is given 1000 mg of a drug that follows first-order kinetics. After 2 hours, the drug level in plasma is 500 mg. What will be the drug level in plasma after 8 hours?

A. 125 mg
B. 62.5 mg (Correct Answer)
C. 0 mg
D. 31 mg

Explanation: ### Explanation **1. Understanding the Correct Answer (B: 62.5 mg)** The drug follows **first-order kinetics**, which means a constant *fraction* of the drug is eliminated per unit of time. The time taken for the plasma concentration to reduce by 50% is the **half-life ($t_{1/2}$)**. * **Step 1 (Find $t_{1/2}$):** The initial dose is 1000 mg. After 2 hours, it becomes 500 mg. Since the concentration halved in 2 hours, the **$t_{1/2} = 2$ hours**. * **Step 2 (Calculate for 8 hours):** Total time elapsed is 8 hours. Number of half-lives ($n$) = $8 \text{ hours} / 2 \text{ hours} = 4$ half-lives. * **Step 3 (Apply the formula):** Amount remaining = $\text{Initial dose} / 2^n$ * After 2 hrs (1st $t_{1/2}$): 500 mg * After 4 hrs (2nd $t_{1/2}$): 250 mg * After 6 hrs (3rd $t_{1/2}$): 125 mg * **After 8 hrs (4th $t_{1/2}$): 62.5 mg** **2. Why Other Options are Incorrect** * **Option A (125 mg):** This is the concentration after 6 hours (3 half-lives). * **Option C (0 mg):** This would occur in **Zero-order kinetics** (where a constant *amount* is eliminated). If this were zero-order, 250 mg would be lost every hour, reaching zero at 4 hours. * **Option D (31 mg):** This is the approximate concentration after 10 hours (5 half-lives). **3. High-Yield Clinical Pearls for NEET-PG** * **First-order Kinetics:** Most drugs follow this. $t_{1/2}$ is **constant** and independent of dose. Clearance is constant. * **Zero-order Kinetics (Non-linear):** Rate of elimination is constant regardless of concentration. Examples: **WATT** (**W**arfarin/Whiskey (Ethanol), **A**spirin (high dose), **T**heophylline, **T**olbutamide, **P**henytoin). * **Steady State:** It takes **4–5 half-lives** to reach steady-state concentration ($C_{ss}$) and the same amount of time to completely eliminate a drug from the body.

Question 89: Drugs interact with their receptor sites by forming which type of bond?

A. Coordinate covalent bonds
B. Covalent bonds
C. Ionic bonds (Correct Answer)
D. Van der Waals forces with basic drugs only

Explanation: **Explanation:** The interaction between a drug and its receptor is a dynamic process governed by chemical bonding. **Why Ionic Bonds are Correct:** Ionic bonds are the **most common initial interaction** between a drug and its receptor. Most drugs are weak acids or weak bases that exist in an ionized state at physiological pH. These charged drug molecules are attracted to oppositely charged amino acid residues on the receptor surface (electrostatic attraction). Ionic bonds are strong enough to initiate the binding process but are easily reversible, allowing the drug to dissociate from the receptor once the biological effect is achieved. **Analysis of Incorrect Options:** * **A & B (Covalent/Coordinate Covalent Bonds):** These are the strongest chemical bonds. While some drugs (e.g., Aspirin, Phenoxybenzamine, Organophosphates) bind covalently, this is **uncommon** because it results in irreversible binding. Most therapeutic drug actions must be reversible to prevent toxicity and allow for termination of effect. * **D (Van der Waals forces):** These are very weak, short-range attractive forces. While they are crucial for the "best fit" and specificity of a drug within a receptor pocket, they are not limited to "basic drugs only" and are usually secondary to initial ionic stabilization. **High-Yield NEET-PG Pearls:** * **Order of Bond Strength:** Covalent > Ionic > Hydrogen > Van der Waals. * **Reversibility:** Most drugs bind via **weak, reversible bonds** (Ionic, Hydrogen, Van der Waals) to allow for fine-tuned physiological control. * **Irreversible Examples:** Aspirin (COX enzyme), Omeprazole (H+/K+ ATPase), and Organophosphates (AChE) are classic examples of covalent (irreversible) binding.

Question 90: Even in large dosages used in malaria, quinine does not cause toxicity because why?

A. It enters in fat cells
B. Elevated plasma alpha acid glycoprotein (Correct Answer)
C. Deposited in infected RBCs
D. Excreted rapidly in urine

Explanation: ### Explanation The correct answer is **B. Elevated plasma alpha acid glycoprotein.** **Mechanism and Concept:** Quinine is a basic drug that primarily binds to **Alpha-1 Acid Glycoprotein (AAG)** in the plasma. In patients with acute malaria, AAG levels significantly increase because it is an "acute-phase reactant." This elevation leads to an increase in the protein-bound fraction of quinine, thereby **decreasing the free (unbound) fraction** of the drug in the plasma. Since only the free drug is pharmacologically active and capable of causing toxicity, the elevated AAG acts as a protective buffer, allowing patients to tolerate high dosages without experiencing severe side effects like cinchonism. **Why other options are incorrect:** * **A. It enters in fat cells:** Quinine is not highly lipophilic; it has a large volume of distribution but primarily binds to tissues like the liver, kidneys, and muscles, not specifically fat cells. * **C. Deposited in infected RBCs:** While quinine does concentrate in erythrocytes to exert its antimalarial effect, this sequestration is not the primary mechanism that prevents systemic toxicity. * **D. Excreted rapidly in urine:** Quinine is primarily metabolized by the liver (CYP3A4). Only a small fraction is excreted unchanged in the urine, and its half-life is actually prolonged in severe malaria. **High-Yield Clinical Pearls for NEET-PG:** * **Acidic drugs** (e.g., NSAIDs, Warfarin, Phenytoin) bind primarily to **Albumin**. * **Basic drugs** (e.g., Quinine, Lidocaine, Propranolol) bind primarily to **Alpha-1 Acid Glycoprotein**. * **Cinchonism:** The classic triad of quinine toxicity includes tinnitus, visual disturbances, and headache. * **Hypoglycemia:** A common side effect of quinine due to the stimulation of pancreatic beta cells to release insulin.

Practice by Chapter

Absorption and Bioavailability

Practice Questions

Drug Distribution and Protein Binding

Practice Questions

Biotransformation and Metabolism Pathways

Practice Questions

Renal and Non-renal Excretion

Practice Questions

Compartment Models

Practice Questions

Dose-Response Relationships

Practice Questions

Drug Efficacy and Potency

Practice Questions

Drug Tolerance and Tachyphylaxis

Practice Questions

Population Pharmacokinetics

Practice Questions

Pharmacokinetic Variability

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free